The Zurich-based company Xlife Sciences AG will in future receive 10 percent of all licensing revenue – up to a maximum amount of 300 million euros – from Baliopharm AG, a BioTech firm headquartered in Basel. This agreement applies to the entire range of agents developed by Baliopharm AG, according to a press release issued by Xlife Sciences. With this transaction, Xlife has a direct interest in the future success of Baliopharm. The BioTech firm is a leading player in the market for antibody therapies aimed at treating acute and chronic inflammatory diseases.
On December 18, 2020, Baliopharm AG received authorization from the Australian public health authority to start a Phase I study for its active ingredient atrosimab. This drug is used to treat non-alcoholic steatohepatitis (NASH), which is the most common form of liver disease and can in severe cases lead to cirrhosis of the liver.
Around 1.5–2 million people in Germany suffer from at least a mild form of this disease. Globally, the figure is more than 115 million people. This could even double by 2030, the company explains, citing an estimate produced by the Global Liver Institute. Accordingly, Baliopharm has its sights set on a huge market.
In the field of research and development for the life sciences industry, Xlife Sciences AG regards itself as a bridge to healthcare markets. Together with industrial partners or academic institutions, the company leads projects through the proof-of-concept phase. As detailed in the press release, this therefore allows investors to get directly involved at a very early stage in the further development of future-oriented technologies.